Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomics in T2-high severe asthmatics treated with biologics: Comparison between anti-IgE, anti-IL-5 and anti-IL-5R-targeted treatments.

ABSTRACT: Background : Biologic therapies have transformed severe asthma management, particularly for T2-high asthma. We aimed to investigate blood proteomics and transcriptomics after biologic treatment. Methods : A prospective study was conducted on 35 patients with severe T2-high asthma treated with mepolizumab (n=9), benralizumab (n=14), or omalizumab (n=12). Evaluations occurred at baseline and after 16 weeks (omalizumab) or 24 weeks (mepolizumab, benralizumab) of treatment. Blood samples were collected. Gene expression was analyzed via Illumina TruSeq RNA Prep, with RNA sequencing on the Illumina NovaSeq-6000 platform. Results : RNA-seq analysis revealed 86 down-regulated genes common to both mepolizumab and benralizumab, primarily associated with eosinophils, basophils, and the purinergic receptor signaling pathway. Additionally, there was evidence of gene regulation involved in antiviral immunity. However, specific gene modulation was observed for benralizumab (114 genes) and mepolizumab (68 genes). Changes following omalizumab treatment were minimal, with only three significantly down-regulated genes. Conclusion : While omalizumab showed minimal quantifiable effects on gene expression, mepolizumab and benralizumab—despite exhibiting distinct profiles—both induced down-regulation of genes related to eosinophil and basophil biology and purinergic signaling pathways, alongside up-regulation of genes involved in innate antiviral immunity.

ORGANISM(S): Homo sapiens

PROVIDER: GSE298740 | GEO | 2025/12/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Inflammatory Epithelial and Macrophage Pathways Underlie Residual Asthma Exacerbations in Urban Children Treated with Mepolizumab

Project description:While biologic therapies targeting type 2 (T2) inflammation reduce acute exacerbation rates in children with asthma and T2 inflammation, exacerbations still occur, and the underlying molecular mechanisms are poorly defined. We aimed to identify multiple distinct molecular mechanisms implicated in asthma exacerbations by characterizing respiratory illnesses among urban children with eosinophilic asthma enrolled in a clinical trial comparing treatment with mepolizumab versus placebo

2025-08-07 | GSE292059 | GEO

Comparison of coding RNA expression of blood eosinophils from mepolizumab- or omalizumab-treated severe asthmatic patients and from healthy controls

Project description:RNA-seq comparison of coding RNA expression in blood eosinophils from patients with severe allergic eosinophilic asthma treated with mepolizumab with those of healthy controls and matched severe asthmatic patients receiving omalizumab.

2021-12-17 | E-MTAB-10190 | biostudies-arrayexpress

Transcriptomic response to ex vivo IL33 stimulation of blood eosinophils from mepolizumab- or omalizumab-treated patients

Project description:Coding RNA expression of blood eosinophils from mepolizumab- or omalizumab-treated patients stimulated ex vivo with IL-33 for 6 hours and of directly processed non-stimulated blood eosinophils from the same samples (paired design)

2021-12-17 | E-MTAB-10189 | biostudies-arrayexpress

High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab Treatment in Severe Asthma

Project description:Background Although the type 2 biologics mepolizumab and dupilumab show clinical efficacy in severe asthma, their influence on circulating lymphocytes is largely unknown. Here, we studied their impact on type 2 lymphocytes in severe asthma. Methods We performed high-parameter flow cytometry analysis of peripheral blood mononuclear cells from 40 patients with severe asthma before, and after 4 and 12 months of mepolizumab (n = 33) or dupilumab (n = 7) treatment, focusing on type 2 lymphocytes. Additionally, we performed single-cell RNA sequencing (scRNA-seq) (n = 3) and stimulation experiments of type 2 lymphocytes (n = 3) to explore transcriptional and functional changes associated with mepolizumab treatment. Results Mepolizumab treatment increased circulating type 2 innate lymphoid cell (ILC2), type 2 T helper (Th2) and type 2 cytotoxic (Tc2) cell frequencies, skewing ILC2 towards a CD117low signature with high CD62L expression, and Th2/Tc2 cells towards a CD45RA−CD62L+ central memory phenotype. Dupilumab-treated patients also showed increased frequencies of total ILC2 and CD117low ILC2. Mepolizumab treatment reduced the expression of tissue homing receptors CXCR4 in ILC2, and GPR183 in ILC2, Th2, and Tc2 cells while enhancing their type 2 cytokine producing capability in response to alarmins. Conclusion Mepolizumab increases the frequencies of circulating ILC2, Th2, and Tc2 cells, with reduced tissue homing receptor expression but increased type 2 cytokine production potential. This reveals a potentially new mechanism for how mepolizumab reduces airway inflammation by re-directing trafficking of inflammatory type 2 lymphocytes away from airway-homing, with implications for the possibility of achieving biologics-free remission in asthma.

2025-08-06 | GSE304665 | GEO

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent with Immune Based Therapy: A Systems Approach Phase 2 (MUPPITS-2)

Project description:A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (MUPPITS-2). ClinicalTrials.gov Identifier: NCT03292588

2022-08-13 | GSE192861 | GEO

Latent MicroRNA Networks in Asthma Endotypes [HuGene-1_0]

Project description:Transcriptome analysis of whole blood from subjects with asthma and controls The presence or absence of type 2 inflammation (T2) biomarkers is used to identify T2-high and T2-low endotypes in the clinic. Despite the clinical relevance of these endotypes, the molecular mechanisms of T2-low asthma remain poorly understood. Specific microRNAs may regulate transcriptomic networks associated with asthma endotypes.

2025-12-01 | GSE287879 | GEO

Latent MicroRNA Networks in Asthma Endotypes [NS_H_miR_v3a]

2025-12-01 | GSE287880 | GEO

RHINOVIRUS INFECTION OF THE AIRWAY EPITHELIUM ENHANCES MAST CELL IMMUNE RESPONSES VIA EPITHELIAL-DERIVED INTERFERONS

Project description:Rationale: Mast cells (MCs) within the airway epithelium in asthma are closely related to airway dysfunction, but crosstalk between airway epithelial cells (AECs) and MCs in asthma remains incompletely understood. Human rhinovirus (HRV) infections are key triggers for asthma progression and AECs from individuals with asthma may have dysregulated anti-viral responses. Objectives: We utilize primary phenotyped AECs in an ex vivo coculture model system to examine crosstalk between AECs and MCs following epithelial HRV infection. Methods: Primary AECs were obtained from children with asthma (n=11) and healthy children (n=10), differentiated at air-liquid interface, and cultured in the presence of laboratory of allergic diseases-2 (LAD2) MCs. AECs were infected with HRV serogroup A 16 (HRV16) for 48 hours. RNA isolated from both AECs and MCs underwent RNA-sequencing (RNAseq) analysis. Direct effects of epithelial-derived interferons on LAD2 MCs were examined by qPCR. Results: MCs increased expression of pro-inflammatory and anti-viral genes in AECs. AECs demonstrated a robust antiviral response following HRV16 infection that resulted in significant changes in MC gene expression, including upregulation of genes involved in anti-viral responses, leukocyte activation, and type-2 (T2) inflammation. Subsequent ex vivo modeling demonstrated that IFN-β induces MC IL13 expression. The effects of AEC phenotype were small relative to the effects of viral infection and the presence of MCs. Conclusions: There is significant crosstalk between AECs and MCs, which are present in the epithelium in asthma. Epithelial-derived interferons not only play a role in viral suppression, but further alter MC immune responses including specific T2 genes.

2022-06-22 | GSE206680 | GEO

Lin-CD117+CD34+FceRI+ progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti-IgE therapy

Project description:Background: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterised by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage-CD34hiCD117int/hiFcεRI+ cells in blood have previously been shown to represent a mast cell precursor. Methods: We enumerated FcεRI-, FcεRI+ and FcεRIhi lineage-CD34+CD117+ cells using flow cytometry in blood of patients with CSU (n=55), including 12 patients receiving omalizumab and 43 not receiving omalizumab (n=43). Twenty-two control samples were studied. Disease control and patient response to omalizumab was evaluated using the Urticaria Control Test. We performed single cell RNA sequencing (scRNA-seq) on lineage-CD34hiCD117hi blood cells from a subset of patients with CSU (n=8) and healthy controls (n=4). Results: CSU patients had more Lineage-CD34+CD117+FcεRI+ blood cells than controls. Lineage-CD34+CD117+FcεRI+ cells were significantly higher in patients with CSU who had an objective clinical response to omalizumab when compared to patients who had poor disease control 90 days after initiation of omalizumab. scRNA-seq revealed that lineage-CD34+CD117+FcεRI+ cells contained both lymphoid and myeloid progenitor lineages, with omalizumab responsive patients having proportionally more myeloid progenitors. The myeloid progenitor lineage contained small numbers of true mast cell precursors along with more immature FcεRI- and FcεRI+ myeloid progenitors. Conclusion: Increased blood CD34+CD117+FcεRI+ cells may reflect enhanced bone marrow egress in the setting of CSU. High expression of these cells strongly predicts better clinical responses to the anti-IgE therapy, omalizumab.

2024-04-30 | GSE261424 | GEO

Identification of Bronchial Epithelial Genes Associated with Type-2 Eosinophilic Inflammation in Asthma

Project description:Airway inflammation has a critical role in asthma pathogenesis and pathophysiology. Yet, the molecular pathways contributing to airway inflammation are not fully known, particularly Type-2 (T2) inflammation characterized by both eosinophilia and FeNO levels. Here, we seek to identify genes whose level of expression in epithelial brushing samples is associated with both bronchoalveolar lavage (BAL) eosinophilia and generation of FeNO. We used a segmental allergen bronchoprovocation (SBP-Ag) procedure in asthma subjects, and RNA-sequencing (RNA-seq) analyses of BAL cells and brushing samples before and 48 h after SBP-Ag. Allergen bronchoprovocation increased FeNO levels which correlated with eosinophilia but not neutrophilia. Thirteen genes were identified in brushing samples, whose expression changed in response to SBP-Ag and correlated with both airway eosinophilia and FeNO levels after SBP-Ag. Among these 13 genes, the epithelial cell product, CDH26 was a candidate to contribute to the amplification of T2 inflammation as reflected by eosinophilia and FeNO, and causal mediation analyses with pro-T2 and pro-eosinophilic cytokine mediators in BAL fluids. Among the genes associated with reduced eosinophila and FeNO, HEY2 is known to enhance cell proliferation, migration, invasion, and EMT, as well as to reduce apoptosis. This unbiased RNA-seq analysis in subjects with allergic asthma has revealed several epithelial cell genes that may be critical for the development or augmentation of T2 inflammation in asthma, particularly CDH26.

2025-01-06 | GSE264325 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data